Comparison of three commercial PSA assays: results of restandardization of the Ciba Corning method.

Background: Consistency in prostate-specific antigen (PSA) quantitation by different PSA test manufacturers would minimize potential clinical confusion. The Ciba Corning ACS PSA2 calibration has been adjusted for alignment with a proposed international standard and clinical concordance with the Hybritech Tandem R assay. Herein we evaluate the clinical effectiveness of this recalibrated PSA test by comparing it with the IMx (Abbott Laboratories) and Tandem R (Hybritech) assays.

Multicenter comparison of the diagnostic performance of free prostate-specific antigen.

Objectives: This study examined the multicenter clinical performance of noncomplexed (free) prostate-specific antigen (PSA) in men presenting with total PSA values between 2.5 to 20 ng/mL.

Methods: Prebiopsy serum samples were obtained from 1,081 consecutively accrued, histologically diagnosed men between the ages of 40 and 75 years with total PSA values falling between 2.

Age-specific prostate-specific antigen: a reassessment.

Background: Our objective was to compare expected survival benefits when screening for prostate cancer with PSA, using an age-specific bound relative to a cutoff of 4.0 ng/ml.

Methods: We used a decision analysis modeling the cancer yield in a cohort screened by both screening tests, and the survival of cancer cases given screen detection and in the absence of screening.

Serum basic fibroblast growth factor in men with and without prostate carcinoma.

Background: Angiogenesis is essential for the growth of neoplasms. Increased vascularity has been associated with human prostatic carcinoma stage and has been shown to offer prognostic information. Basic fibroblast growth factor (bFGF) is a potent angiogenic inducer expressed in malignant prostate tissue.

Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen.

Objectives: This study examined the clinical significance of non-complexed (free) prostate-specific antigen (PSA) in the differential diagnosis of prostate cancer with an emphasis on patients with total PSA values between 4.0 and 10.0 ng/mL (the diagnostic gray zone).